If you're truly long-term-minded, then the potential for a September swoon doesn't deter you. And that may well be for the best. Although this is supposed to be a tough time of year -- this year in particular, in light of the big rally from last year's lows -- stocks still log gains about half
Current times are among the most challenging for creating a retirement portfolio or ensuring that retirees get positive returns (adjusted for inflation). Even with aggressive contractionary monetary policies, inflation has remained stubbornly high in the United States. In the current scenario, individuals will witness erosion of purchasing power by investing in risk-free assets.
It’s essential to invest in stocks. However, it would be equally suicidal to go significantly overweight on high-beta stocks or growth stocks. A good idea is to invest in high-yield dividend stocks for....More>>>
I’ll start by stating that any month is a great month to buy dividend aristocrat stocks. September is proving to be a volatile month in terms of economic headwinds posed by Covid-19. That has essentially been true for all of 2021, let’s hope 2022 is better.
But that volatility leaves investors searching for stability. That is of course where dividend aristocrat stocks come into the picture: Steady in the best of times and the worst of times.
We often come across the term “dividend aristocrats” while searching for general investment advice, but what....More>>>
Calamos Advisors LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 2.0% during the second quarter, HoldingsChannel.com reports. The firm owned 645,980 shares of the company's stock after acquiring an additional 12,694 shares during the quarter. Calamos Adv
ProShare Advisors LLC lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 13.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 1,352,532 shares of the company's stock after selling 207,457 shares during the quarter. Abb
Wambolt & Associates LLC boosted its position in AbbVie Inc. (NYSE:ABBV – Get Rating) by 3.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,401 shares of the company's stoc